ABSTRACT: Background. Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (SCC) has a better outcome than most head neck squamous cell carcinomas (HNSCCs) and an HPV-positive lymph node metastasis likely has an HPV-positive oropharyngeal SCC origin. Determining HPV-status in cervical lymph nodes by fine-needle aspiration cytology (FNAC) may be useful for diagnosis. Methods. FNACs from 66 patients with neck masses were prospectively examined for HPV DNA and HPV16 mRNA by a polymerase chain reaction (PCR)-based assay, and the data correlated to diagnosis and HPVstatus obtained from histopathological specimens. Results. Aspirates from 17 of 66 patients, later diagnosed with HPVpositive oropharyngeal SCC, were HPV16 DNA-positive. HPV16 mRNA was detected in all cases with extractable RNA. All remaining FNACs, including 18 branchial cleft cysts, were HPV DNA-negative. HPV DNA status in the aspirates showed perfect concordance with corresponding biopsies. Conclusion. HPV16 DNA detection in fine-needle aspirations from neck masses is reliable and HPV16 DNA in a metastasis is a strong indicator of an HPV-positive oropharyngeal SCC.
INTRODUCTION
About 700,000 individuals are affected by head and neck squamous cell carcinoma (HNSCC) per year, and each year close to 400,000 individuals die of the disease. 1 Because of its poor prognosis, therapy has been intensified resulting in an increasing number of side effects, such as mucositis, xerostomia, dysphagia, and osteoradionecrosis; effects seriously compromising the patients' quality of life. [2] [3] [4] [5] Oropharyngeal squamous cell carcinoma (SCC) is a subset of HNSCC, of which HPV-positive oropharyngeal SCC includes mainly tonsillar SCC and base of tongue (BOT) cancer, whereas other oropharyngeal SCC sites predominantly are HPV-negative. 5, 6 The incidence of HPV-positive oropharyngeal SCC has increased considerably in the past decades in several Western countries. Furthermore, patients with HPV-positive oropharyngeal SCC have considerably better outcome than those with HPV-negative oropharyngeal SCC and HNSCC in general, with a 5-year overall survival of approximately 80%, whereas the prognosis of HPVnegative HNSCC is less favorable at approximately 40% 5-year overall survival. [20] [21] [22] [23] [24] Thus, it has been proposed that HPV status could influence management of HNSCC, and that deescalation of treatment might be possible in patients with HPV-positive tumors. [3] [4] [5] The first symptom of an HNSCC is often an enlarged cervical lymph node, where fine-needle aspiration cytology (FNAC) of the neck mass can reveal SCC and a clinical examination and/or CT scan usually identifies the primary tumor location. If not, the patient is submitted to endoscopy, including biopsies of the BOT, nasopharynx, and tonsillectomy in search for the primary. If no primary tumor is found (ie, cancer of unknown primary [CUP] ), the traditional routine has been to proceed with a neck dissection to confirm the cytological diagnosis. If a cervical lymph node metastasis is human papillomavirus (HPV)-positive, it has an HPV-positive oropharyngeal SCC origin, in most cases. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] In many centers today, one generally presumes that finding HPV in the cytology of the metastasis proves that the CUP is an HPV-positive tonsillar SCC or BOT SCC and the patient is treated accordingly. [38] [39] [40] [41] [42] In this context, one condition that needs special attention is the "atypical" cytology from earlier infected branchial cleft cysts, which, in fact, is reactive, but can mimic cancer. There are, however, limited prospective studies examining whether HPV is found in other clinical conditions (ie, branchial cleft cysts, benign lymph nodes, or in metastasis from HNSCC), other than tonsillar SCC or BOT SCC. Consequently, if HPV-positivity in cystic neck lesions is specific for HPV-positive tonsillar SCC and BOT SCC, neck dissection could be safely avoided in patients with CUP if cytology clearly indicates SCC. Detection of HPV E6 and E7 mRNA in freshfrozen material is considered the best method of determining HPV-driven neoplasms. 43 However, fresh-frozen material is often difficult to achieve, especially in a clinical setting. Instead, HPV status is usually determined from formalin-fixed paraffin-embedded (FFPE) diagnostic biopsies or surgical resections by detection of HPV DNA using different polymerase chain reaction (PCR)-based methods or by in situ hybridization. Overexpression of the surrogate marker p16 using immunohistochemistry (IHC) has also been applied, but today the use of HPV DNA and p16 overexpression in combination is preferred and more reliable to avoid false-positive results when determining HPV-driven cancer. 4, 43 There are several studies investigating HPV DNA testing in FNAC, but most have been of retrospective character and have mainly included patients with confirmed SCC. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Furthermore, to our knowledge, no attempts have been made yet to detect HPV mRNA in FNAC, allowing for safer detection of HPV-driven cancer. Moreover, the presence of HPV in benign conditions (eg, branchial cleft cysts), has not been investigated thoroughly before.
Therefore, the purpose of this study was to prospectively analyze HPV status in FNAC biopsies from benign and malignant conditions. FNACs from patients with suspected HNSCC or benign neck lesions were therefore tested for the presence of HPV DNA, and HPV mRNA when possible, and the obtained data were compared with that acquired from analysis of corresponding histopathological specimens. Furthermore, we investigated whether presence of HPV16 DNA in the FNAC could prospectively predict an HPV-positive oropharyngeal SCC as the final diagnosis.
MATERIALS AND METHODS

Patients and samples
Between 2013 and 2016, FNAC material was prospectively obtained at the Karolinska University Hospital from 66 patients with suspected HNSCC or with neck masses suspicious for metastasis who had enough material remaining for testing after cytological diagnostic analysis had been performed. All patients had given informed consent according to ethical permission from the Stockholm Regional Ethics committee. FNAC was performed on patients with neck masses suspicious for metastatic lesions in 64 cases and from the primary tumor in 2 cases using 23 to 27-gauge needles. One part of the aspirate was used to prepare smears, which were air-dried or ethanol fixed and stained by May-Grundwald-Giemsa or Papanicolaou technique, respectively, for cytologic diagnosis. When more than 0.5 mL of cystic content was obtained, the remaining material was fresh-frozen at 2208C and later used for the present study. Patients characteristics: age, sex, final diagnosis, TNM classification, and HPV-status (if available) were collected from the patients records after the samples had been analyzed in order to keep the investigators blinded during analysis.
DNA extraction from fine-needle aspiration cytology samples
Genomic DNA was extracted from between 20 and 50 lL of the thawed aspirates using the QIAmp DNA micro kit (Qiagen, Hilden, Germany) in accord with the manufacturer's instructions. One blank per sample was added and treated the same way as the samples in order to control for cross contamination.
DNA extraction from formalin-fixed paraffin-embedded biopsies
In some oropharyngeal SCC cases, FFPE biopsies from a primary tumor were available for comparison with the FNAC from the corresponding lymph node metastasis, or, in 1 case, FNAC from the primary tumor instead. DNA had, for other purposes, been extracted from these FFPE specimens using the High Pure FFPE DNA Isolation Kit (Roche AB, Stockholm, Sweden) in accord with the manufacturer's instructions and then diluted to 2 ng/lL and stored at 2208C. For further details, see the Results section.
Human papillomavirus DNA amplification and detection from fine-needle aspiration cytology and formalin-fixed paraffin-embedded material A multiplex PCR covering 27 HPV types was performed using broad spectrum GP51/GP61-primers in order to amplify the preserved L1 region of the HPV genome and, in parallel, primers for the cellular b-globin gene, to assure the presence of amplifiable DNA in the samples, as described previously. [44] [45] [46] In addition, the E6 gene of HPV16 and HPV33 was amplified with specific primers to detect HPV also in rare cases, with deletions in the L1 region of these, in HNSCC most commonly, HPV types. 46, 47 The 10 ng of DNA was used for each reaction. Samples with known concentrations of HPV DNA (100, 10, and 1 genome/lL) were included as positive controls, whereas distilled water was used as a negative control and for background. DNA detection was performed using a bead-based multiplex assay on a MagPix instrument, as previously described. 44 In total, beads for 27 HPV types were included, as well as beads binding to HPV16 E6, HPV33 E6, and b-globin. 47 The raw data was further processed in Excel (Microsoft, Redmond, WA). Results were reported as mean fluorescent intensity (MFI) and only MFIs above (background*1.5) 115 were considered HPV-positive in order to avoid false-positive results. Samples with a b-globin MFI >30 were considered to contain enough DNA to evaluate the presence of HPV. 46 Determination of human papillomavirus status in cytology and formalin-fixed paraffin-embedded specimens in the clinic and p16 status obtained from patients' case reports
Presence of HPV DNA was tested in the clinic on either cytology material or FFPE material. Genomic DNA was extracted from cytology smears, liquid aspirates, or FFPE material, using a verified semiautomated Maxwell 16 protocol (Promega, Madison, WI). Real-time TaqMan PCR was performed in duplicates to detect the 7 most common high-risk HPV genotypes. 48 Amplification of a fragment of the HCK proto-oncogene as a control reference gene was performed to trace the quality of DNA and exclude a false-negative result.
In addition, information regarding p16 analyses was collected from patient records. IHC staining of histopathological material from tissue specimens from the patient's primary tumor or branchial cleft cyst using the JC8 antibody (Santa Cruz Biotechnology, Dallas, TX) had been performed on 19 patients. Samples were considered p16-positive if >70% of tumor cells showed strong staining. 49 
Human papillomavirus mRNA analysis
In HPV-positive aspirates, if material remained after DNA extraction, RNA was extracted from 20 to 40 lL of the aspirates using the RNeasy Micro kit (Qiagen, Hilden, Germany) in accord with the manufacturer's instructions. In some remaining HPV-positive aspirates, the previously extracted DNA was subjected to DNAse treatment using the RNeasy MiniElute Cleanup kit (Qiagen, Hilden, Germany). The complementary DNA (cDNA) was then synthesized from all samples containing adequate material using the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA) in accord with the manufacturer's instructions. Random hexamer primers were used. HPV16 E2, E5, E6*I, E6*II, and E7 RNA were amplified using PCR and detected by the multiplex bead-based assay, as described for E2, E5, and E7 previously. 50 To also amplify E6*I and *II cDNA, the following primers were included in the PCR: HPV16 E6_194.F bp194-214 5 0 -GTGTACTG-CAAGCAA CAGTTA-3 0 , HPV16 E6_565.R bp 565-545 5 0 -GC ATGATTACAGCTGGGTTTC-3 0 , and HPV16 E6_445.R bp 445-425 5 0 -TTCTTCAGGACA CAGTGGC TT-3 0 . To detect E6*I and *II transcripts in the bead-based assay, beads coupled to the following probes were included in the assay: E6*Ip 5 0 -AGTTAATACACCTCACGT-3 0 and E6*IIp 5 0 -TTGATGATCTCACGTCGC-3 0 . The assay also included detection of the cellular genes U1A, as a positive control for the presence of amplifiable RNA, and a bglobin intron sequence to verify that no DNA remained, as earlier described. 50 
RESULTS
Presence of human papillomavirus DNA and mRNA was detected in fine-needle aspiration cytology samples PCR amplifiable DNA, determined by the presence of b-globin DNA, was obtained from all 66 FNAC samples for analysis. HPV16 DNA was found in 17 of 66 samples (26%). No other HPV types were detected.
In addition, E7 and E6*I HPV mRNA was detectable in 7 of 16 of the HPV16 DNA-positive tested samples. More specifically, in 12 of 16 HPV16 DNA positive aspirates, material remained after DNA extraction and, here, RNA was extracted from 20 to 40 lL of the aspirates, whereas, in 4 cases, the previously extracted DNA was subjected to DNAse treatment (for details see the Materials and Methods section). In 1 case, RNA was not extracted. In the remaining 9 of 16 samples, the presence or absence of HPV mRNA could not be evaluated because the signal for the mRNA of the housekeeping gene U1As was absent, indicating that there was insufficient RNA for testing.
Cytological diagnosis and final diagnosis according to patient records
When the analysis above was completed, the patients' records were examined. The cytological diagnosis of the specimens and the final diagnosis of the patients are displayed for oropharyngeal SCC in Table 1 , for other malignancies in Table 2 , and for benign conditions in Table 3 . Figure 1 depicts the histopathology of a tonsillar SCC. Patient characteristics are summarized in Table 4 . Initial cytological diagnosis showed 28 cases of SCC, 5 cases of other malignancies, and 2 cases of atypical squamous cells, whereas 30 cytologies were deemed benign and 2 were defined as unclear processes. For final tissue diagnosis, a total of 37 patients had malignancies, of which 20 were oropharyngeal SCC (13 tonsillar SCCs, 6 BOT SCCs, and 1 tumor originating from the back wall of the oropharynx) and 29 patients had benign conditions, including 18 branchial cleft cysts. Thus, 1 cytology deemed as benign had a malignancy as the final diagnosis (a BOT SCC), the 2 unclear processes were both malignant, whereas, in the remaining cases, the cytological classification of benign or malignant were correct.
Human papillomavirus status according to patient records
HPV testing had been performed on cytology samples using the above-mentioned PCR method in 40 of 66 patients according to the patients' records. Fifteen patients, all with tonsillar SCC or BOT SCC, were HPVpositive, whereas HPV was not detected in 3 oropharyngeal SCCs (Table 1 ), in 7 cases of malignancies other than oropharyngeal SCC (Table 2) , or in the 15 tested branchial cleft cysts (Table 3 ). In addition, p16 analyses had been carried out on FFPE specimens from biopsy or resection tissue samples in 19 cases (13 p16-positive oropharyngeal SCCs, 3 p16-negative oropharyngeal SCCs, 1 p16-negative branchial cleft cyst, and 1 p16-negative mobile tongue SCC) and PCR had been performed on FFPE material in 2 cases (1 HPV-positive oropharyngeal SCC and 1 HPV-negative oropharyngeal SCC; Tables  1-3) .
Human papillomavirus status in formalin-fixed paraffinembedded material
In addition, FFPE biopsy material from 10 patients with oropharyngeal SCC (3 with tonsillar SCCs, 6 with BOT SCCs, and 1 with the tumor originating from the back wall of the oropharynx) were available and had been tested for HPV DNA for other purposes with the same bead-based multiplex assay as used for testing the FNACs. Nine results were HPV-positive, all tonsillar SCCs and BOT SCCs, whereas the tumor originating from the back wall was HPV-negative (Table 1) .
Human papillomavirus DNA-status in fine-needle aspiration cytology in correlation to diagnosis All 17 patients with HPV-positive FNAC were diagnosed with an HPV-positive oropharyngeal SCC and all of these were either tonsillar SCC or BOT SCC ( Table   TABLE 3 1), and summarized with regard to age and sex in Table  4 , and in comparison to all patients in Table 5 . The presence of HPV DNA was, thus, indicative of an HPVpositive oropharyngeal SCC (Tables 1 and 5 ). Three patients with oropharyngeal SCCs had HPV-negative FNACs, whereas 2 patients were diagnosed with HPVnegative oropharyngeal SCC originating from the tonsils and 1 patient with an HPV-negative oropharyngeal SCC originating from the back wall of the oropharynx with overgrowth of 1 ipsilateral tonsil. Patients diagnosed with oropharyngeal SCC with HPV-positive FNACs tended to be younger and more often of male sex than patients with oropharyngeal SCCs with HPV-negative FNACs (Table  6 ) or patients diagnosed with other types of malignancies (Table 4) . Importantly, HPV was not detected in the 17 patients diagnosed with other malignancies than oropharyngeal SCC, or in the 29 patients diagnosed with benign conditions, including the 18 branchial cleft cysts (Tables 2, 3 , and 5).
Comparison of human papillomavirus detection in cytological and histopathological samples
The HPV status in the FNAC tested by us showed perfect concordance with the HPV status of the 40 cytology samples tested in the clinic (Tables (1-3) ). Furthermore, 19 patients had histopathological material tested for HPV and/or p16. All 19 cases were tested using p16 IHC at the clinic and 10 of these were tested using PCR by us with HPV-positive status correlating 100% with p16-positive status. The HPV status in the cytological material showed perfect concordance when compared to the HPV status in the histopathological material (see Tables (1-3) ).
DISCUSSION
In this study, it has been shown prospectively that HPV16 DNA-detection in FNAC is reliable and that presence of HPV16 in the aspirates is highly indicative of an HPV-positive oropharyngeal SCC. Notably, HPV DNA was not observed in other HNSCC subsets or in benign conditions, including branchial cleft cysts, confirming the specificity of HPV for oropharyngeal SCC. In addition, HPV DNA status in cytological specimens showed perfect concordance with HPV DNA status in the histopathological material, highlighting the usefulness of HPV DNA testing in cytological specimens for distinguishing HPVpositive tonsillar SCC and BOT SCC from other HNSCCs and certain benign conditions. However, using the present procedures, for several reasons, the presence of HPV16 mRNA in HPV16 DNA-positive samples was possible to confirm in only 7 of 16 of the cases.
That HPV detection in FNAC is possible has been shown in several previous studies. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] However, most of these studies had a retrospective character and used archival material. [25] [26] [27] [28] [29] [30] 32, 33, 35 Some studies were prospective, and, in this study, different commercial methods available for detection of HPV in gynecological cytology specimens were used. Furthermore, different conditions were used to process the material, and very few benign samples were included in the testing. 30, 31, 36, 37 In contrast, in this study, a broader approach was applied, in which we included both fresh malignant and benign leftover material from standard cytological procedures. Moreover, cytology samples were analyzed, both by us and by the pathology department, using different methods and the specimens showed perfect concordance with regard to HPV status. The material tested by us was collected in PBS, fresh-frozen at 2208C, and examined by a standard, noncommercial, PCR-based method potentially available for all laboratories. The described procedure proves to be simple, inexpensive, and feasible to work well in a clinical setting.
That presence of HPV in FNAC is indicative of an oropharyngeal SCC has been shown in a few studies, generally with very good specificity (90% to 100%), but average sensitivity (50% to 70%) and our results are in line with these. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] However, most of these studies were retrospective, and, importantly, almost exclusively included patients with verified SCCs. It is possible that HPV is present in other types of neck masses as well, which might affect the specificity and sensitivity of HPV testing. Therefore, we conducted our study prospectively and included a broad cohort of patients with enlarged cervical lymph nodes/masses showing that presence of HPV is highly indicative of an HPV-positive oropharyngeal SCC in this context as well. The absence of HPV in the lymph node does not rule out an HPV-positive oropharyngeal SCC, but the detection of HPV is a strong signal indicating malignancy. This was illustrated by the 71-year-old male patient in which initial cytology suggested a benign cyst, but when the FNAC was HPV-positive (when later tested by us), the patient was subsequently found to harbor an HPV-positive BOT SCC (Table 1) . When the original cytology material was reviewed, there were few atypical squamous epithelial cells. One month after initial testing, cytology was repeated and showed metastasis of SCC.
In this study, we found that 85% of the oropharyngeal SCCs were HPV-positive. This percentage is slightly higher than what we previously found for HPV-positive oropharyngeal SCC in Stockholm between 2008 and 2012 (74%). 51 The reason for this difference is unclear but could be explained by the limited number of patients in the study or that there was a dominance of cystic metastasis, common in HPV-related metastatic disease.
E6 and E7 are the two most important transforming proteins of HPV, and the expression of HPV16 E6*I and E7 mRNA in all 7 samples with evaluable mRNA indicate that these tumors are indeed HPV16 driven. Especially, the expression of the E6*I transcript has been associated with tumor progression. 52 The lack of RNA detection in the remaining samples could be the consequence of the high variability of cell contents in FNAC samples and to the limitation of the assay sensitivity in case of low cell number. Alternatively, it can be attributable to the unstable nature of RNA and to suboptimal sample storage condition. Last, some FNAC samples often seem to be partially necrotic, an unfavorable condition for preserving RNA integrity. Further exploration of HPV RNA detection in FNAC, using more sensitive detection methods and/or different storing medium or temperature, might be worthwhile.
HPV DNA in FNAC was not found in patients with any other condition than HPV-positive oropharyngeal SCC, confirming the specificity of HPV16 for the oropharynx, in an unselected cohort. Furthermore, HPV was not found in 18 branchial cleft cysts, further establishing that determining HPV DNA status using FNAC could be a useful supplement for management of this condition and clearly safer than examining p16 status because the few studies examining p16 expression in branchial cleft cysts have shown that a large proportion (28% to 43%) overexpress p16, although being HPV DNA-negative. 53, 54 Notably, as mentioned above, 1 patient who was initially deemed as having a benign cyst by cytology (and not HPV tested on this cytology), was later diagnosed with an HPV-positive/p16-positive BOT SCC (Table 1) . This highlights the usefulness of HPV DNA testing also cystic lesions with benign cytological morphology, something that is infrequently performed today and needs to be investigated further.
One limitation of the study was that aspirates were received only if there was enough material left after standard diagnostic procedures. It is possible that this resulted in a preponderance of cystic lesions, in which material was more ample, in our study. However, because a main objective of this study was to analyze HPV status in branchial cleft cysts, this does not pose a problem for this objective or for the comparison between cytological and histopathological methods. However, it might have overestimated the proportion of HPV-positive oropharyngeal SCCs prone to form cystic metastasis.
Another drawback of this study was the limited number of patients included. It is likely that the specificity for predicting an HPV-positive oropharyngeal SCC would not have been 100% in a larger cohort, because although HPV is most common in oropharyngeal SCC, it is also present in a minor fraction of hypopharyngeal cancer, laryngeal cancer, and cancer of the mobile tongue. 47, [55] [56] [57] [58] Nevertheless, HPV-induced HNSCC outside the oropharynx is rare and a very large cohort would have been required to find these other types of cases.
Another limitation was that only 19 patients had both cytological and histopathological material available for comparison. However, the majority of the specimens from these patients had been HPV tested by multiple cytological and histopathological methods and showed perfect concordance, regardless of the method used. Furthermore, in this study, we found a perfect correlation between overexpression of p16 and positive HPV DNA status. In a larger cohort, this would have most likely not been the case, because approximately 10% of HPV DNA-negative oropharyngeal SCC overexpress p16, whereas 14% of HPV-positive oropharyngeal SCC is p16-negative. 59 To conclude, HPV16 DNA detection in FNAC from cervical lymph nodes and other neck masses is reliable and presence of HPV16 DNA is a strong indicator of an HPV-positive oropharyngeal SCC. HPV DNA was not found in other malignancies than oropharyngeal SCC or in benign conditions, including branchial cleft cysts. Thus, the analysis of HPV DNA status in FNAC is useful for the management of patients with suspected HNSCC or branchial cleft cysts and, in HPV16 DNA-positive cases, could guide further diagnostic procedures toward the oropharynx. HPV RNA detection in FNAC, as performed here, was not as sensitive as HPV DNA detection, but should be explored further for possible future clinical use.
